In summary, the combination of N8-PE24 with tamoxifen or paclitaxel efficiently inhibited tumor growth in 231-PRLR xenografts model, highlighting the potential broad-spectrum applicability of this therapeutic strategy on BC. Here, PRLR is linked to breast cancer.